Success Metrics

Clinical Success Rate
77.8%

Based on 21 completed trials

Completion Rate
78%(21/27)
Active Trials
6(16%)
Results Posted
119%(25 trials)
Terminated
6(16%)

Phase Distribution

Ph phase_1
17
46%
Ph phase_3
4
11%
Ph phase_2
13
35%
Ph early_phase_1
1
3%

Phase Distribution

18

Early Stage

13

Mid Stage

4

Late Stage

Phase Distribution35 total trials
Early Phase 1First-in-human
1(2.9%)
Phase 1Safety & dosage
17(48.6%)
Phase 2Efficacy & side effects
13(37.1%)
Phase 3Large-scale testing
4(11.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

21 of 28 finished

Non-Completion Rate

25.0%

7 ended early

Currently Active

6

trials recruiting

Total Trials

37

all time

Status Distribution
Active(6)
Completed(21)
Terminated(7)
Other(3)

Detailed Status

Completed21
Terminated6
Active, not recruiting5
unknown3
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
37
Active
6
Success Rate
77.8%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (2.9%)
Phase 117 (48.6%)
Phase 213 (37.1%)
Phase 34 (11.4%)

Trials by Status

completed2157%
terminated616%
unknown38%
withdrawn13%
recruiting13%
active_not_recruiting514%

Recent Activity

6 active trials
Showing 5 of 37
active_not_recruitingphase_2

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

NCT02923778
active_not_recruitingphase_2

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625
completedphase_1

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

NCT02779855
active_not_recruitingphase_1

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

NCT04599062
terminatedphase_1

Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin

NCT04163952
View all 37 trials

Clinical Trials (37)

Showing 20 of 37 trialsScroll for more
NCT02923778Phase 2

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

Active Not Recruiting
NCT02978625Phase 2

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Active Not Recruiting
NCT02779855Phase 1

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Completed
NCT04599062Phase 1

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

Active Not Recruiting
NCT04163952Phase 1

Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin

Terminated
NCT06660810Phase 2

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec

Active Not Recruiting
NCT02965716Phase 2

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Active Not Recruiting
NCT03802604Early Phase 1

Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer

Completed
NCT03554044Phase 1

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Completed
NCT04068181Phase 2

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

Completed
NCT03086642Phase 1

Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

Completed
NCT03663712Phase 1

Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies

Completed
NCT02509507Phase 1

Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

Completed
NCT02453191Phase 1

TVEC and Preop Radiation for Sarcoma (4 ml Dose)

Completed
NCT03300544Phase 1

Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

Terminated
NCT01740297Phase 1

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

Completed
NCT03256344Phase 1

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Completed
NCT03842943Phase 2

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

Recruiting
NCT02756845Phase 1

Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

Completed
NCT04185311Phase 1

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Terminated

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
37